Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., . . . Lingvay, I. (2019). Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular diabetology, 18(1), 73-12. https://doi.org/10.1186/s12933-019-0871-8
Citace podle Chicago (17th ed.)Leiter, Lawrence A., Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst, a Ildiko Lingvay. "Cardiovascular Risk Reduction with Once-weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial." Cardiovascular Diabetology 18, no. 1 (2019): 73-12. https://doi.org/10.1186/s12933-019-0871-8.
Citace podle MLA (9th ed.)Leiter, Lawrence A., et al. "Cardiovascular Risk Reduction with Once-weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial." Cardiovascular Diabetology, vol. 18, no. 1, 2019, pp. 73-12, https://doi.org/10.1186/s12933-019-0871-8.